Sorrento Therapeutics. has filed a patent for a stable oral liquid pharmaceutical composition of celecoxib that does not precipitate in simulated gastric fluid. The composition, when administered, provides pain relief in humans within 2 hours. GlobalData’s report on Sorrento Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Stable oral liquid pharmaceutical composition of celecoxib for pain relief
A recently filed patent (Publication Number: US20240016732A1) outlines a method for providing pain freedom in human subjects suffering from various types of pain. The method involves administering a stable oral liquid pharmaceutical composition containing celecoxib and medium chain glyceride, resulting in pain freedom within 2 hours post-administration. The pain relief achieved is reported to be at least 10% greater compared to commercially available treatments like VIOXX 25 and 50 mg, as well as CAMBIA 50 mg. The pain freedom is specified to last between 2 to 24 hours, catering to a wide range of pain types including acute pain, migraine pain, neuropathic pain, and various others. The therapeutically effective amount of celecoxib in the composition ranges from 80 mg to 300 mg, ensuring optimal pain relief outcomes.
Additionally, the patent also describes a method for providing partial pain relief in human subjects using a similar oral liquid pharmaceutical composition containing celecoxib and medium chain glyceride. This method leads to partial pain relief within 2 hours post-administration, with the relief being at least 10% greater compared to existing treatments like VIOXX and CAMBIA. The partial pain relief is maintained for at least 4 hours and targets a wide array of pain conditions similar to the pain freedom method. The therapeutically effective amount of celecoxib in this composition ranges from 80 mg to 300 mg, ensuring effective pain management for various pain types. The inclusion of solubilizers and polar solvents in the composition further enhances its efficacy in providing partial pain relief to individuals suffering from different forms of pain.
To know more about GlobalData’s detailed insights on Sorrento Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
